Towa Pharmaceutical Cuts FY2026 Net Profit Forecast 71% on Goodwill Impairment

Towa Pharmaceutical Cuts FY2026 Net Profit Forecast 71% on Goodwill Impairment

Towa Pharmaceutical Co., Ltd. (TSE:4553) has revised downward its earnings forecast for the fiscal year ending March 2026, citing operational challenges at subsidiary Sansei Pharmaceutical and a substantial goodwill impairment charge.

The company attributed the revision to deteriorating performance at consolidated subsidiary Sansei Pharmaceutical, where domestic health food business profitability has declined and new application ventures face intensifying overseas competition. Additionally, post-launch sales of Towa’s own products have underperformed expectations. Most significantly, the company will record a goodwill impairment loss of JPY 14.7bn, directly reducing net profit attributable to parent company shareholders by 70.6% to JPY 5.2bn. However, ordinary income (keijo rieki)—a Japan-specific profit metric including non-operating items—is projected to rise 10.7% to JPY 28.0bn, supported by derivative valuation gains of JPY 5.3bn that offset the operating profit decline.

For investors, the impairment reflects strategic challenges in integrating Sansei Pharmaceutical and executing planned synergies. While the substantial one-time charge pressures near-term earnings per share, declining to JPY 105.63/share from JPY 359.57/share, the company has maintained its dividend forecast unchanged. Management indicated it will provide further guidance on FY2027 impacts at the full earnings announcement.

Source: Original filing (TDnet) | 日本語版

This article is for informational purposes only and does not constitute investment advice. Always verify against the original filing.